<DOC>
	<DOCNO>NCT02067026</DOCNO>
	<brief_summary>Study hypothesis Aleurone-rich food supplementation modifies cardiovascular metabolic risk profile gut microbiota subject high BMI Primary objectives trial evaluate whether wheat Aleurone-rich food supplementation modifies ( 1 ) fast homocysteine level ; ( 2 ) human biofluid primary metabolite ; ( 3 ) human biofluid secondary ( microbiota-derived ) metabolite ; ( 4 ) fecal bile acid fecal sterol concentration . Secondary objective evaluate whether wheat Aleurone-rich food supplementation modifies ( 1 ) fecal microbiota , ( 2 ) plasma urine MS base metabolite profile ; ( 3 ) total cholesterol , triglyceride , LDL- HDL-cholesterol level ; ( 4 ) serum glucose insulin level ; ( 5 ) anthropometric index ; ( 6 ) urinary isoprostane level ; ( 7 ) marker intestinal permeability plasma ; ( 8 ) inflammation Study Design Placebo-controlled , randomize , double-blind parallel trial Criteria Enrollment Inclusion criterion : Aged 18-65 year ; BMI &gt; 27 kg/m^2 . Good General health . Exclusion criterion : Fasting blood glucose &gt; 300 mg/dl ; triglyceride &gt; 500 mg/dl ; uncontrolled hypertension ( blood pressure [ BP ] &gt; 160/100 mm Hg antihypertensive therapy ) ; long term medical therapy ; food intolerance ; alcohol intake &gt; 5 drink per day use narcotic substance ; use dietary supplement , pro pre- biotics ; special diet ; pregnancy , tobacco smoking . Methodology After run-in phase two week , participant randomize receive supplementation either wheat Aleurone-rich food ( 27 g Aleurone/day ) placebo 4 week double-blind manner . Clinical visit , clinical test , blood drawing perform overnight fast start run-in phase ( visit T-1 ) U.O.S . di Dietetica e Nutrizione Clinica , St Chiara , Trento . Clinical test , blood drawing , stool urine collection perform visit begin end treatment period ( T0 T1 ) U.O.S . di Dietetica e Nutrizione Clinica , St chiara , Trento . A 4 day-food diary record collect visit T0 T1 . Efficacy Assessments Arterial BP ; BMI ; ratio waist hip circumference ; food questionnaire ; blood sample analysis ( total cholesterol , triglyceride , HDL LDL cholesterol , serum glucose insulin , C-RP , plasma LPS , LPS specific IgG , CD14 , LPS-binding protein ) ; urinary isoprostane ; urinary plasma metabolite profiling ; fecal microbiota analysis . Safety Assessments . Adverse event . Statistical analysis . Post-intervention data compare ANOVA use General Linear Model baseline covariate . Data skew distribution log transform analysis . Simple multiple linear regression use determine relationship variable independent t-tests perform evaluate difference report compliance group . Results express mean +/- SEM difference consider significant P &lt; 0.05.. Duration Dosing . Subjects make three visit study ( start run-in phase - visit T-1- , begin - visit T0 , week 2 - end treatment period - visit T1 , week 6 ) . Duration treatment period four week ; daily Aleurone consumption 27 g target .</brief_summary>
	<brief_title>Measuring Impact Dietary Supplementation With High Fiber , High Antioxidant Aleurone Biomarkers Cardiovascular Disease Gut Microbiota Adults With High Body Mass Index</brief_title>
	<detailed_description>STUDY OBJECTIVES The general aim study evaluate whether wheat aleurone-rich food supplementation modifies cardiovascular metabolic risk profile subject increase metabolic risk . Primary objective trial evaluate whether wheat aleurone-rich food supplementation modifies : 1. total plasma homocysteine ( tHcy ) 2. plasma metabolite related homocysteine metabolism ( include betaine , dimethylglycine , methionine , choline , folate , riboflavin , vitamin B6 ) ; 3. human biofluid secondary ( microbiota derive ) polyphenol metabolite ; 4. fecal bile acid fecal sterol concentration . 5. faecal microbiota profile generate use Illumina sequence Secondary objective evaluate whether wheat aleurone-rich food supplementation modifies : 1. plasma urine MS base metabolite profile ; 2. total cholesterol , triglyceride , LDL- , HDL-cholesterol level ; 3. serum glucose insulin level ; 4. anthropometric index ; 5. urinary isoprostane level ; 6. marker intestinal permeability plasma ; 7 . C-reactive protein level marker inflammation Study Design Overview Endpoints The study set placebo-controlled , randomize , double-blind parallel trial 2 test food , wheat Aleurone-rich food control food ( placebo ) . The primary secondary endpoint give section , STUDY OBJECTIVES . Design Overview Participants identify recruit U.O.S . di Dietetica e Nutrizione Clinica , St Chiara , APSS Trento Fondazione Edmund Mach . Participants inform study aim procedures pre-screened basis inclusion/exclusion criterion . If eligible , sign inform consent enter study visit T-1 , perform clinic 8.00 9.00 a.m. , clinical biochemical evaluation health status perform . If subject still eligible study accord exclusion criterion , include trial randomise receive active supplementation placebo visit T0 , 2 week later ( run-in period ) . A dietary counselling administer visit T-1 T0 . Participants advise follow Mediterranean dietary habit practice moderate physical activity . Clinical visit , clinical test , blood drawing perform overnight fast start run-in phase ( visit T-1 ) . Clinical test , blood drawing , stool urine collection perform , visit T0 ( week 2 ) T1 ( week 6 ) . A four day food diary distribute filled four consecutive day study participant visit T0 T1 . Each participant subject : - Clinical biochemical evaluation exclude possible disease status ( T-1 , week 0 ) : anamnestic questionnaire , ECG , hemocrome , creatinine , liver enzymes ) . - Blood drawing ( 30 ml ) biochemical analysis ( T-1 -week 0- , T0 - week 2- T1 - week 6- ) . - Stool 24 hr urine collection biochemical analysis ( T0 - week 2- T1 - week 6- ) . - Anthropometric evaluation : systolic diastolic blood pressure , pulse rate , height weight BMI calculation waist hip circumference ( T-1 -week 0- , T0 - week 2- T1 - week 6- ) . All visit perform clinic 8.00 9.00 a.m. , fast status . Each visit last 1 hr . Participants ask modify current diet , exception supplement introduction substitution correspond food . They also ask avoid drug , supplement integrator immediately communicate monitor disease status change drug prescription ( new current drug therapy ) . Participant recruitment Participants identify recruited U.O.S . di Dietetica e Nutrizione Clinica , St Chiara , APSS Trento Fondazione Edmund Mach . They include worker institution member public . Participants inform study aim procedures pre-screened basis inclusion/exclusion criterion . If eligible , sign inform consent enter study visit T-1 , clinical biochemical evaluation health status perform . If subject remain eligible study accord inclusion/exclusion criterion , include trial randomize receive active supplementation placebo visit T0 , two week later ( run-in period ) . Supplementation After run-in phase two week , participant randomize receive supplementation either wheat Aleurone-rich food placebo food four week double-blind manner . Dietary counseling Dietary counseling administer visit T-1 T0 . Participants advise follow Mediterranean dietary habit practice moderate physical activity . Follow-up The intervention include four week treatment period . Clinical visit , clinical test , blood drawing perform overnight fast visit T-1 - week 0- . Clinical test , blood drawing , stool urine collection perform visit T0 T1 ( T0 day supplementation , T1 week 4 treatment either aleurone supplement food placebo supplement food ) . A one year recall food frequency questionnaire administer visit T-1 . A one week recall food frequency questionnaire perform visit T0 T1 . Clinical evaluation Electrocardiogram . A 12-lead ECG perform screen . Electrocardiographs review interpreted U.O.S . di Dietetica e Nutrizione Clinica , St Chiara , APSS Trento . Arterial blood pressure ( BP ) measure accord guide-lines hypertension ISH/WHO 2004 . The 'OMRON HEM705CP Oscillometric blood pressure monitor ' use . Subjects keep rest seat 10 minute measure blood pressure right arm ; The first measure discharge ; second third measure follow first 2 minute , relax naked arm arm angle level heart . The mean last two measure use analysis . Weight height measure standard scale , attach altimeter height measurement record equal closest 100 g 1 cm , necessary , respectively . Measures carry subject without shoe , coat heavy dress . BMI calculate kg/m2 . Waist ( Umbilical ) circumference measure accord National Institutes Health , National Heart , Lung , Blood Institute . Clinical guideline identification , evaluation , treatment overweight obesity adult ; evidence report . In practice , subject stand erect abdomen relax , arm side foot together , waist circumference measure , near 0.1 cm , level midway lower rib margin iliac crest tape around body horizontal position . Hip circumference measure bitrochanteric level . The ratio waist hip circumference ( WHR ) calculate . Questionnaires . All information collect record validated questionnaire , include personal identification , medical history , information risk factor CVD , drug use , physical activity , dietary habit . Moreover three day food diary collect . Blood sample urine collection Blood ( ≤ 30 ml ) collect antecubital vein , minimal stasis 8.00 9.00 a.m. 12 h fasting , subject refrain smoke least 6 h. 24 h urine collection obtain participant . Urine volume measure 5 aliquot 5 ml store -80°C . Faecal sample collection Feacal sample process within 2 hour sample production . Briefly , 1 g aliquotes faeces mixed RNA-later store -80°C later DNA . Faecal sample also freeze directly -80°C metabolite analysis . Laboratory test ( U.O.S . di Dietetica e Nutrizione Clinica , St Chiara , APSS Trento ) Blood sample centrifuge accord requirement test perform , immediately blood collection . Plasma serum separate , part immediately test remain fraction store -80°C . Cholesterol , triglyceride , HDL cholesterol glucose evaluate chromogenic assay . LDL cholesterol calculate accord Friedewald formula . Insulin level evaluate ELISA . Blood cell count evaluated standard test . C-RP measure nephelometric assay ; F2-isoprostanes measure urine measure oxidant stress , specific EIA kit ( Cayman Chemicals , Ann Arbor , Michigan , USA ) , purification solid phase chromatography ( SepPack column ) . Laboratory test ( Fondazione Edmund Mach [ FEM ] ) Plasma LPS , LPS specific IgG , CD14 , LPS-binding protein , urinary 8-Isorpostane measure spectrophotometrically use commercial ELISA kit . Urinary plasma metabolite profiling ( FEM ) . Urine blood ( plasma serum ) sample subject targeted metabolomics ( UPLC-MS/MS non-volatile compound GC-MS/MS volatile compound ) untargeted metabolomics ( ULPC-Q-TOF-MS Nano-FTMS-Q-TOF non-volatile GC-TOF volatile compound ) ( Vanza et al. , 2001 2012 ) . For targeted metabolite profile plasma , MS base Biocrates AbsoluteIDQ® p180 Kit use , generate accurate quantitative data 180 human metabolite relate diabetes disease risk . Also specific target analysis apply serum lipid profile , bile acid , SCFA , microbial polyphenol metabolite quantification biofluids ( include faeces ) use UPLC/QqQ-MS/MS ( Vrhovsek et al. , 2012 ) . Fecal microbiota analysis ( FEM ) . Fecal microbiology change assess use 454 pyrosequencing metagenomics . Briefly , follow delivery fecal sample metagenomic DNA extract use FastDNA SPIN Kit FECES MPbio.com . Using universal bacterial primer , V1-V3 region inclusive 16S rRNA gene present within fecal metagenomic DNA amplify subject 454-pyrosequencing . Multiplex Identifier ( MID ) Adaptors use GS FLX Titanium Chemistry - Extended MID Set obtain sequence 600 bp length BLASTED publically available 16S rRNA phylogenetic database use QIIME pipeline ( http : //qiime.org/ ) give good specie level identification human gut microbiota . A total 20,000 usable sequence per fecal sample target . Following quality control microbial ecological analysis , multivariate statistic employ correlate change within fecal microbiota composition structure subject consumption Aleurone supplement food compare control food ( De Filippo et al. , 2010 ) . Quantitative PCR specie group specific primer employ confirm change microbial population identify pyrosequencing metagenomic data . Using qPCR , total bifidobacteria , total enterobacteria , total bacteria lactobacilli fecal sample enumerate . This minimum act independent quality control pyrosequencing . In addition depend see term specie level change pyrosequencing , specie specific primer employ confirm statistically significant difference see upon comparison Aleurone control feed time point . Randomization Blinding Participants , stratify sex randomize aleurone treatment placebo treatment electronic generate number provide statistician . Clinical investigator laboratory personnel blind randomization . Study product ( bread flour , biscuit , RTE cereal ) deliver Cargill blind manner mark either E W differentiate treatment . Test product package similar wrapping daily portion . Placebo food contain ingredient active food except cellulose substitute Aleurone similar latter size , shape color . Treatment The study supplementation introduce daily diet accord participant preference total 27 g Aleurone/day equivalent dose placebo . One bread slice ( 35 g ) contain 4.8 g Aleurone ; one biscuit ( 15 g ) contain 4.5 g Aleurone ; 36 g RTE cereal contain 9 g Aleurone . Placebo food contain ingredient active food except cellulose substitute Aleurone fiber content similar latter size , shape color . The study product ( active placebo ) provide product package label local language study code number , site code number , name manufacturer , patient number , study visit number , batch number , storage instruction , expire date . Products dispense participant visit T0 . Study Duration Scheduling After run-in phase two week , participant randomize Aleurone supplement food group placebo supplement group 4 week dietary intervention.. The overall duration study , include run-in treatment 6 week . Subject recruitment commence upon favourable assessment APSS research ethic committee first subject start run-in period within two week start point . Subjects recruit 6 month period study complete 8 month time first subject recruitment . Discontinuation Criteria Criteria In accordance Declaration Helsinki , ICH Good Clinical Practice Guidelines , United States Food Drug Administration ( FDA ) Regulations , subject right withdraw study time reason without prejudice his/her future medical care physician institution . The Investigator Sponsor also right withdraw subject study ( see ) . Additionally , Sponsor may choose terminate study time reason . Should subject ( subject 's legally authorize representative ) decide withdraw , effort make complete report observation thoroughly possible . A complete final evaluation make time subject 's withdrawal , reason withdrawal record attempt make perform follow-up evaluation . Subjects may remove study reason include follow : - significant protocol violation part Investigator - significant noncompliance part subject - refusal subject continue treatment observation - unacceptable toxicity - decision Investigator termination subject 's best medical interest - unrelated medical illness complication - pregnancy - evidence alcohol substance abuse Subjects discontinue withdrawn study replace . Procedure Early Discontinuation Should subject discontinue prior completion study , reason , date discontinuation obtain . The date last dose study product also obtain . In event early discontinuation , follow procedure perform : - Clinical test ( systolic diastolic blood pressure , pulse rate , height weight BMI calculation , waist hip circumference ) , - Blood drawing , stool urine collection - A 1 week food recall questionnaire In event subject return follow-up visit , site attempt contact subject phone follow adverse event . If subject withdraws consent receive study product , encourage remain study without receive treatment collection safety data . Accountability Procedures Study Product The study product ( active placebo ) provide product package label local language study code number , site code number , name manufacturer , product code number , study visit number , batch number , storage instruction , expire date . Products dispense participant visit T0 . Bread frozen portion 2 bun biscuit freeze portion 2 biscuit defrost home participant prior consumption . Randomization Code Maintenance Randomization cod participant keep seal envelope FEM . Product code information keep seal envelope Cargill . Source Data Control All data collect course study obtain primary source record write electronic document subject 's medical file . The result clinical exam , laboratory finding , ECG tracing record subject 's electronic medical file . No data enter directly onto case report form ( CRF ) without transfer prior source write electronic record . Selection Withdrawal Subjects Inclusion Criteria At least one follow condition : Aged 18-65 year ; BMI &gt; 27 kg/m^2 . Exclusion Criteria Subjects exclude study participation meet follow exclusion criterion : fasting blood glucose &gt; 300 mg/dl ; triglyceride &gt; 500 mg/dl ; uncontrolled hypertension ( BP &gt; 160/100 mm Hg antihypertensive therapy ) ; cardiovascular disease ( myocardial infarction , percutaneous transluminal coronary angioplasty coronary artery bypass grafting , unstable angina pectoris , stoke , peripheral arterial disease ) ; hypo- hyperthyroidism ; acute inflammatory disease ; severe gastrointestinal disease ; heart , liver , renal pulmonary failure life threaten disease prognosis &lt; 5 year ; chronic use systemic corticosteroid , anti-coagulants , anti-inflammatory , lipid lower anti-diabetics drug ; treatment within previous 6 week medication know affect lipoprotein level fecal microbiota ( specifically , antibiotic ) ; food intolerance ; alcohol intake &gt; 5 drink per day use narcotic substance ; use antioxidant vitamin mineral supplement ; special diet ; pregnancy , smoking . Concomitant Drug Therapy Any therapy receive subject within one month prior start study and/or administer study regard concomitant therapy . Such treatment must document appropriate CRF page subject ' medical record . Any change concomitant therapy study must clearly recorded reason change document . Use follow medication allow study : Corticosteroids , anticoagulant , antinflammatory , lipid lower antidiabetic drug ; medication know affect lipoprotein level fecal microbiota ( specifically antibiotic ) , supplement , probiotic , prebiotics , herb , except management adverse event . Subject Compliance To evaluate compliance supplementation , urinary phenol measure subject supplement Aleurone-rich food time T0 T1 . Moreover , unused empty packet end week accompany self record use portion return investigator . Recording Reporting Adverse Events Adverse Events Adverse event , solicit unsolicited , record throughout study 30 day follow last treatment study product . An adverse event ( AE ) physical clinical change disease experience subject time course study , whether consider relate use study product . This include onset new illness exacerbation pre exist condition . Abnormal laboratory value test result generally consider AEs , unless induce clinical sign symptom require therapeutic intervention . Adverse event follow carefully resolve . A verbatim description event , relationship study product , whether event also record serious adverse event ( SAE ) must report Adverse Event CRF AE record subject 's chart . Any AEs occur first study procedure entire course study , final study procedure report , whether deem related study product . Each entry must include onset end date time , seriousness , severity , relationship study product , action/outcome . All AEs record use terminology define Medical Dictionary Regulatory Activities ( MedDRA ) , version 10 . Statistical analysis Planned Enrollment Justification The sample size 34 determine detect change 0.4 μmol/L total homocysteine ( tHcy ) plasma standard variation 0.5 μmol/L ( take Price et al. , 2010 ) use Snedecor Cochran equation α 0.05 1-β 0.9 ( Dell et al. , 2002 ) . Taking consideration previous study aleurone healthy individual Price et al. , ( 2010 ) , need account drop out , propose recruit 40 individual per treatment group present study . Basal characteristic present group . Eventually residual difference active food placebo group randomization consider adjustment multivariable model analysis . Continuous variable express mean +/- standard deviation median interquartile range percentage categorical variable . Post-intervention data compare ANOVA use General Linear Model baseline covariate . Data skew distribution log transform analysis . Simple multiple linear regression use determine relationship variable independent t-tests perform evaluate difference report compliance group . Results express mean +/- SEM difference consider significant P &lt; 0.05 . The 'intention treat ' principle adopt analysis primary endpoint : evaluation efficacy take account initial randomization independently compliance treatment subject . The main analysis base comparison difference mean level end study subject supplement active food subject give placebo food . The main analysis base comparison difference mean level end study subject supplement active food placebo food supplement . The difference time treatment arm evaluate analysis Variance repeat measure ( GLM Procedure , SAS Institute Inc. SAS/STAT User Guide , Version 9.1.3 WINDOWS . Cary , NC : SAS Institute Inc. 1989 ) . The significance level alpha=0.05 two-tailed . Demographics Baseline Characteristics Demographics baseline characteristic include limited age , gender , race , ethnicity , body weight , height , body mass index , blood pressure dietary habit tabulate use descriptive statistic Baseline Assessments Any abnormal finding baseline electrocardiogram assessment , drug screen , virus screen summarize descriptively . Laboratory Values Laboratory data sample change baseline summarize Visit mean , median , standard deviation , minimum , maximum . DIRECT ACCESS TO SOURCE DATA/DOCUMENTS Regulatory authority may wish conduct audit clinical research activity evaluate compliance principle GCP . A regulatory authority may also wish conduct inspection ( study even completion ) . If inspection request regulatory authority and/or IRB , Investigator must inform Sponsor designee immediately . The Investigator must agree provide regulatory authority access study-related documentation . The Investigator allow Sponsor assist respond citation well receive copy document provide inspector/auditor . ETHICS Institutional Review Board/Ethics Committee Before implement study , protocol inform consent review Comitato etico per le Sperimentazioni Cliniche c/o APSS di Trento . A sign dated statement protocol informed consent approve Comitato etico per le Sperimentazioni Cliniche c/o APSS di Trento must file site study initiation . A listing member Comitato etico per le Sperimentazioni Cliniche c/o APSS di Trento must also file site . Any amendment protocol , administrative one , must approve Comitato etico per le Sperimentazioni Cliniche c/o APSS di Trento . Informed Consent Informed consent form sign . Disclosure Confidentiality By sign protocol , Investigator agree keep information provide Cargill strict confidence request similar confidentiality his/her staff IRB . Study document provide Cargill ( protocol , Investigator Brochures , material ) store appropriately ensure confidentiality . The information provide Cargill Investigator may disclose others without direct write authorization Cargill except extent necessary obtain informed consent subject wish participate trial . DATA HANDLING AND RECORDKEEPING Source data/documentation define first place data record . Any source document must maintain retrievable site . The Investigator must maintain source document subject study . Data collect CRFs trial document anonymous fashion , subject identify subject number initial . If , exception , necessary safety regulatory reason identify subject , Cargill , Investigator bind keep information confidential . All data enter CRFs must legibly record black ink . If correction necessary , make strike incorrect entry single line enter correct information adjacent . The correction must initial dated Investigator designate qualified individual . Any requested information obtain specify protocol explanation omission note CRF . A copy subject 's CRF , along related query , must maintain study site . All information CRFs must traceable source document , generally maintain subject 's file . The source document contain demographic medical information include laboratory data , ECGs , etc. , also copy sign informed consent form , indicate study number title trial . Essential document , list , must retain Investigator period identify Cargill begin study . Cargill notify Investigator/institution study relate record longer require . The Investigator agree adhere document retention procedure sign protocol . Essential document include , limited , protocol , advertising material , AE report , subject source record , IRB correspondence , consent form , curriculum vitaes , monitor visit log , laboratory record , reference range , certification , quality control documentation , pertinent document . Any change addition protocol require write protocol amendment must approve Cargill implementation . If substantial change design study make IRB must notify , necessary , approve change inclusion new subject . All data management procedure detail separate , specifically identify file collectively reference Data Management Plan ( DMP ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>BMI 30 kg/m^2 fast blood glucose &gt; 300 mg/dl ; triglyceride &gt; 500 mg/dl ; uncontrolled hypertension ( BP &gt; 160/100 mm Hg antihypertensive therapy ) ; cardiovascular disease ( myocardial infarction , percutaneous transluminal coronary angioplasty coronary artery bypass grafting , unstable angina pectoris , stoke , peripheral arterial disease ) ; hypo hyperthyroidism ; acute inflammatory disease ; severe gastrointestinal disease ; heart , liver , renal pulmonary failure life threaten disease prognosis &lt; 5 year ; chronic use systemic corticosteroid , anticoagulant , antiinflammatory , lipid lower antidiabetic drug ; treatment within previous 6 week medication know affect lipoprotein level fecal microbiota ( specifically , antibiotic ) ; food intolerance ; alcohol intake &gt; 5 drink per day use narcotic substance ; use antioxidant vitamin mineral supplement ; special diet ; pregnancy ; smoking .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>overweight</keyword>
</DOC>